Integra LifeSciences (IART) Surpasses Q4 Expectations for Earnings and Revenue

Integra LifeSciences Surpasses Earnings Expectations

Integra LifeSciences (IART) reported adjusted earnings of $0.83 per share for the recent quarter, exceeding the Zacks Consensus Estimate of $0.79. In comparison, the company earned $0.97 per share during the same period last year. These results exclude one-time items.

This performance reflects a positive earnings surprise of 4.73%. In the previous quarter, analysts anticipated earnings of $0.43 per share, but Integra delivered $0.54, resulting in a 25.58% surprise.

Over the past year, Integra has outperformed consensus earnings estimates in three out of four quarters.

Operating within the Zacks Medical - Instruments sector, Integra generated $434.93 million in revenue for the quarter ending December 2025, narrowly beating the consensus estimate by 0.13%. This figure is slightly lower than the $442.64 million reported a year earlier. The company has also surpassed revenue expectations three times in the last four quarters.

The immediate impact on Integra’s stock price will largely depend on management’s insights shared during the earnings call, as well as future earnings projections.

Since the start of the year, Integra’s share price has declined by approximately 6.7%, while the S&P 500 has advanced by 1.5%.

What Lies Ahead for Integra?

Despite lagging behind the broader market this year, investors are now considering what the future holds for Integra’s stock.

While there is no definitive answer, one useful indicator is the company’s earnings outlook, which includes both current consensus estimates for upcoming quarters and recent changes to those forecasts.

Research indicates a strong link between short-term stock price movements and trends in earnings estimate revisions. Investors can monitor these changes themselves or use tools like the Zacks Rank, which has a proven history of leveraging earnings estimate trends.

Prior to this earnings announcement, Integra’s estimate revisions were mixed. Although these may shift following the latest report, the current outlook gives Integra a Zacks Rank #3 (Hold), suggesting the stock is likely to perform in line with the market in the near term.

It will be important to watch how analyst estimates for the next quarters and the current fiscal year evolve. Presently, the consensus projects earnings of $0.45 per share on $395.08 million in revenue for the upcoming quarter, and $2.31 per share on $1.68 billion in revenue for the full year.

Investors should also consider the broader industry outlook, as it can significantly influence stock performance. The Medical - Instruments industry currently ranks in the top 30% among more than 250 Zacks industries. Historically, the top half of Zacks-ranked industries outperforms the lower half by more than two to one.

Another company in the same sector, Ekso Bionics (EKSO), has yet to release its results for the quarter ending December 2025.

Ekso Bionics, which specializes in robotic exoskeletons, is anticipated to report a quarterly loss of $0.08 per share, reflecting a year-over-year improvement of 96.2%. The consensus earnings estimate for this period has remained stable over the past month.

Ekso Bionics’ revenue is expected to reach $5.65 million, representing an 11% increase from the previous year’s quarter.

Is Integra LifeSciences a Good Investment?

Thinking about investing in Integra LifeSciences Holdings Corporation (IART)?

Since 1978, Zacks Investment Research has provided investors with independent analysis and tools. Over the past 25 years, the Zacks Rank stock-rating system has delivered an average annual return of +24.08%, more than doubling the S&P 500’s performance from January 1, 1988 through May 6, 2024.